Medical diagnostics pioneer Proteomics International Laboratories has filled its pockets with a further $2.2 million in cash through Australia’s research and development (R&D) rebate scheme.
The company’s technology sits at the forefront of proteomics - protein-based precision medicine - converting routine pathology into biomarker discovery that can predict and redirect patient outcomes long before irreversible health damage sets in.
The latest government cash injection is earmarked to fuel the next phase of the company’s “Promarker” diagnostics platform roll-out across diabetic kidney disease, endometriosis and oesophageal cancer.